. 2022 Nov 17;482(1):149–162. doi: 10.1007/s00428-022-03432-2

Table 2.

Molecular/cytogenetic abnormalities in extranodal MALT lymphomas

Site	Translocations/trisomies	Mutations
Stomach	BIRC3::MALT1 (6–23%) IGH::MALT1 (1–5%) + 3 (11%) + 18 (6%)	NOTCH1 (17%) NF1 (16%) TNFAIP3 (15%) ATM (13%) TRAF3 (13%)
Occular adnexa/orbit	IGH::MALT1 (0–25%) FOXP1::IGH (0–20%) BIRC3::MALT1 (0–10%) + 3 (38%) + 18 (13%)	TNFAIP3 (39%) KMT2D (15%) CREBBP (10%) LRP1B (10%) MYD88 (10%)
Salivary gland	IGH::MALT1 (0–16%) BIRC3::MALT1 (0–5%) BCL10::IGH (0–2%) + 3 (55%) + 18 (19%)	TBL1XR1 (24%) GRP34 (16%) NOTCH2 (11%) SPEN (11%) KMT2C (11%)
Lung	BIRC3::MALT1 (31–53%) IGH::MALT1 (6–10%) BCL10::IGH (2–7%) + 3 (20%) + 18 (4%)	KMT2D (25%) TNFAIP3 (18%) PRDM1 (12%) NOTCH1 (12%) EP300 (11%)
Thyroid	FOXP1::IGH (0–50%) BIRC3::MALT1 (0–17%) + 3 (17%)	TET2 (61%) TNFRSF14 (44%) PIK3CD (23%) SPEN (17%) CREBBP (8%)

Site

Translocations/trisomies

Mutations

Stomach

BIRC3::MALT1 (6–23%)

IGH::MALT1 (1–5%)

+ 3 (11%)

+ 18 (6%)

NOTCH1 (17%)

NF1 (16%)

TNFAIP3 (15%)

ATM (13%)

TRAF3 (13%)

Occular adnexa/orbit

IGH::MALT1 (0–25%)

FOXP1::IGH (0–20%)

BIRC3::MALT1 (0–10%)

+ 3 (38%)

+ 18 (13%)

TNFAIP3 (39%)

KMT2D (15%)

CREBBP (10%)

LRP1B (10%)

MYD88 (10%)

Salivary gland

IGH::MALT1 (0–16%)

BIRC3::MALT1 (0–5%)

BCL10::IGH (0–2%)

+ 3 (55%)

+ 18 (19%)

TBL1XR1 (24%)

GRP34 (16%)

NOTCH2 (11%)

SPEN (11%)

KMT2C (11%)

Lung

BIRC3::MALT1 (31–53%)

IGH::MALT1 (6–10%)

BCL10::IGH (2–7%)

+ 3 (20%)

+ 18 (4%)

KMT2D (25%)

TNFAIP3 (18%)

PRDM1 (12%)

NOTCH1 (12%)

EP300 (11%)

Thyroid

FOXP1::IGH (0–50%)

BIRC3::MALT1 (0–17%)

+ 3 (17%)

TET2 (61%)

TNFRSF14 (44%)

PIK3CD (23%)

SPEN (17%)

CREBBP (8%)

Summarized from Vela et al. [73], Streubel et al. [74], and Remstein et al. [75]